Stockreport

AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights [Yahoo! Finance]

AN2 Therapeutics, Inc.  (ANTX) 
US:NYSE Investor Relations: ir.antheminc.com
PDF First of two boron-based oncology targets to enter development in early 2026 Announced research collaboration with GSK to advance boron-based LeuRS-inhibitors targeti [Read more]